Intellia Therapeutics Inc (NASDAQ:NTLA) CEO Nessan Bermingham sold 336,783 shares of Intellia Therapeutics stock in a transaction on Friday, December 8th. The stock was sold at an average price of $20.78, for a total value of $6,998,350.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Intellia Therapeutics Inc (NASDAQ NTLA) traded up $0.08 during trading hours on Friday, hitting $21.22. The company had a trading volume of 614,091 shares, compared to its average volume of 345,697. Intellia Therapeutics Inc has a 1 year low of $10.83 and a 1 year high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.06. The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company’s quarterly revenue was up 49.0% on a year-over-year basis. During the same period last year, the company earned ($0.22) EPS. analysts predict that Intellia Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.

NTLA has been the topic of several analyst reports. Barclays reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $30.17.

Several large investors have recently modified their holdings of the stock. GSA Capital Partners LLP increased its position in shares of Intellia Therapeutics by 28.9% during the 3rd quarter. GSA Capital Partners LLP now owns 73,100 shares of the company’s stock worth $1,817,000 after purchasing an additional 16,400 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of Intellia Therapeutics by 23.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 60,915 shares of the company’s stock worth $1,514,000 after purchasing an additional 11,398 shares during the last quarter. Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics by 7.0% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock valued at $7,111,000 after acquiring an additional 18,784 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Intellia Therapeutics by 34.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,492 shares of the company’s stock valued at $1,429,000 after acquiring an additional 14,818 shares in the last quarter. Finally, GMT Capital Corp acquired a new position in Intellia Therapeutics in the 3rd quarter valued at about $8,214,000. 49.53% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Intellia Therapeutics Inc (NTLA) CEO Sells 336,783 Shares of Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/08/insider-selling-intellia-therapeutics-inc-ntla-ceo-sells-336783-shares-of-stock.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.